ArticleJournal of medical case reports2025
Liver metastasis from a chromophobe renal cell carcinoma 18 years after initial diagnosis: a case report.
Article in Journal of medical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChromophobe renal cell carcinoma is a rare histological subtype, accounting for only 5-6% of renal cell carcinoma cases. It exhibits low aggressiveness and has an overall favorable prognosis with a very low risk of developing metastatic disease. Genetic syndromes such as Birt-Hogg-Dubbé may be associated with this renal cell carcinoma subtype. Owing to limited clinical data, therapeutic regimens for advanced chromophobe renal cell carcinoma are often extrapolated from treatment protocols for clear cell renal cell carcinoma or studies combining several non-clear cell renal cell carcinoma types. CASE PRESENTATION: We report a case of a 54-year-old Austrian male patient presenting with metastatic liver disease from chromophobe renal cell carcinoma, confirmed by biopsy, 18 years after the initial diagnosis of a non-metastasized, grade 2, pNO, pT2 tumor with R0 resection. The patient underwent regular follow-up examinations and had no clinical symptoms at the time of recurrent disease diagnosis. Family history for genetic syndromes was negative. The multidisciplinary tumor board decided to treat the patient with a novel first-line palliative therapy using combined immuno-/tyrosine kinase therapy with pembrolizumab/lenvatinib. A multiphasic computed tomography scan performed 3 months after initiation of therapy showed a complete response.
conclusionAlthough chromophobe renal cell carcinoma typically has excellent progression-free survival and overall survival rates in localized disease, those patients with larger tumors or those with sarcomatous features, as well as PT53 mutations, seem to have worse outcomes due to metastatic development. This case report affirms that patients with chromophobe renal cell carcinoma exhibiting these risk factors should undergo closer and long-term follow-up after curative surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.